Mechanism of action The specific mechanisms by which<unk>  exerts its effect on survival in patients with severe sepsis is not completely understood. In vitro data suggest that activated protein C exerts an antithrombotic effect by inhibiting factors Va and VIIIa, and that it has indirect profibrinolytic activity by inhibiting plasminogen activator inhibitor-1 (PAI-1). In vitro data also suggest that activated protein C may exert an anti-inflammatory effect by inhibiting tumor necrosis factor production, by blocking leukocyte adhesion to selectins, and by limiting the thrombin-induced inflammatory responses within the microvascular endothelium. Pharmacokinetics If the dosage guidelines are followed, the drug reaches peak plasma levels after two hours and is completely cleared from plasma two hours after termination of the infusion period. Endogenous plasma protease inhibitors deactivate<unk> . Therefore, no dose adjustment is needed in elderly patients, or in patients with renal or hepatic dysfunction. Presentation Xigris is the current brand name of activated<unk> , manufactured by Eli Lilly. The drug is sold in vials containing either 5 mg or 20 mg, respectively. The United States' Food and Drug Administration (FDA) approved the drug in 2001 as was the case with the drug authorities in many other countries.
Drotrecogin alfa
Efmoroctocog alfa
Vonicog alfa
Etelcalcetide
Susoctocog alfa
Moroctocog alfa
Sulfatide
Velmanase alfa